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RATIONALE: The major risk factor in the development of chronic obstructive pulmonary disease
(COPD) is cigarette smoke (CS) with ∼ 50% of smokers developing the disease. Thus,
interventions to prevent/reverse CS-induced lung damage offer a novel treatment option in
COPD and related lung diseases. CS has very recently been shown to deplete lung levels of the
newly identified endogenous anti-inflammatory signalling molecule, hydrogen sulfide (H2S).
Lung/sputum H2S levels negatively correlate with smoking pack years, are depleted in COPD,
and further lowered after CS exposure. During oxidative stress (such as occurs in the COPD
lung, or after CS exposure) H2S-synthesising enzymes translocate to mitochondria and H2S
stimulates ATP synthesis, inducing cytoprotective mechanisms and indicating mitochondrial H2S
is beneficial to the lung in regulating cellular bioenergetics. Pharmacological inhibition or genetic
silencing of endogenous H2S synthesising enzymes exacerbates lung inflammation,
mitochondrial damage and oxidative injury indicating that impairment of H2S synthesis and/or
loss of H2S bioavailability is detrimental in COPD and negatively impacts on mitochondrial
health. METHODS: We have investigated whether novel slow release selective mitochondria-
targeted H2S delivery molecules (mtH2SD) we have developed (e.g. AP39 and RT01) could
suppress and/or reverse CS-induced inflammation and lung injury. To examine the effects of
mtH2SD on suppressing COPD development, female C57Bl/6 mice were exposed to CS (12
cigarettes, b.i.d, 5 days/week) or air for 8 weeks with (1.0 mg/kg i.p.,q.d.). The effects of mtH2SD
on reversing CS-induced lung inflammation and remodelling were also assessed: mice were
exposed to CS for 8 weeks as described above followed by either 4 weeks of rest or continued
CS exposure, each with mtH2SD (1.0 mg/kg i.n.,q.d.). Airway inflammation was assessed by
differential enumeration of inflammatory cells in bronchoalveolar lavage fluid (BALF) and BALF
IL-1β levels determined by ELISA. Lung function was assessed by forced oscillation and forced
manoeuvre techniques. RESULTS: CS exposure lowered lung H2S levels and induced
inflammasome activity. mtH2SD significantly (p<0.05) suppressed CS-induced alveolar
destruction, fibrosis and improved lung gas exchange (DFCO). Administration of mtH2SD to mice
with experimental COPD (at 8 weeks), reversed CS-induced lung neutrophil, eosinophil and
macrophage infiltration, loss of lung function, and partially reversed airway resistance in both
 
continued smoking and after rest models. CONCLUSIONS: Targeting H2S to mitochondria may
be a novel therapeutic approach to prevent and/or reverse mitochondria-driven inflammation and
lung injury in COPD and related diseases.
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